WO2000008043A3 - Prevention and treatment of viral disease - Google Patents

Prevention and treatment of viral disease Download PDF

Info

Publication number
WO2000008043A3
WO2000008043A3 PCT/US1999/017487 US9917487W WO0008043A3 WO 2000008043 A3 WO2000008043 A3 WO 2000008043A3 US 9917487 W US9917487 W US 9917487W WO 0008043 A3 WO0008043 A3 WO 0008043A3
Authority
WO
WIPO (PCT)
Prior art keywords
frms
fusion
antibodies
present
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/017487
Other languages
French (fr)
Other versions
WO2000008043A9 (en
WO2000008043A2 (en
Inventor
Jack H Nunberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Montana – Missoula
Original Assignee
University of Montana – Missoula
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU57715/99A priority Critical patent/AU5771599A/en
Priority to KR1020017001483A priority patent/KR20010085326A/en
Priority to IL14121199A priority patent/IL141211A0/en
Priority to EP99945011A priority patent/EP1102788A4/en
Priority to CA002338983A priority patent/CA2338983A1/en
Priority to JP2000563676A priority patent/JP2002522448A/en
Application filed by University of Montana – Missoula filed Critical University of Montana – Missoula
Priority to BR9912732-6A priority patent/BR9912732A/en
Publication of WO2000008043A2 publication Critical patent/WO2000008043A2/en
Publication of WO2000008043A3 publication Critical patent/WO2000008043A3/en
Anticipated expiration legal-status Critical
Publication of WO2000008043A9 publication Critical patent/WO2000008043A9/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to the generation of Fusion-Related Molecular Structures (FRMS) which comprise one or more transitional fusion-related determinants. Highly effective vaccines may be constructed which present the fusion-related determinants to the immune system that engender unique antibodies capable of potently neutralizing a broad range of primary isolates, from worldwide locations and from different phylogenetic viral clades. The present invention provides methods for formation, isolation and purification of the FRMS as well as the use of such FRMS in a variety of compositions and methods, including, for example, as vaccine immunogens, diagnostics, and therapeutics. The present invention concerns FRMS capable of eliciting neutralizing antibodies to viral pathogens and primary isolates of a virus. Antibodies raised to the FRMS can be used to study the molecular pathway toward fusion of the virus and host cell and to identify points of a possible antibody-mediated blockade to that pathway. The invention also relates to the use of antibodies of the invention for anti-viral agents, blood product additives, contraceptive additives passive immunization in post-exposure treatments or fetus immunization.
PCT/US1999/017487 1998-08-03 1999-08-03 Prevention and treatment of viral disease Ceased WO2000008043A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
KR1020017001483A KR20010085326A (en) 1998-08-03 1999-08-03 Prevention and treatment of viral disease
IL14121199A IL141211A0 (en) 1998-08-03 1999-08-03 Prevention and treatment of viral disease
EP99945011A EP1102788A4 (en) 1998-08-03 1999-08-03 PREVENTION AND TREATMENT OF VIRAL PATHOLOGY
CA002338983A CA2338983A1 (en) 1998-08-03 1999-08-03 Prevention and treatment of viral disease
JP2000563676A JP2002522448A (en) 1998-08-03 1999-08-03 Prevention and treatment of viral diseases
AU57715/99A AU5771599A (en) 1998-08-03 1999-08-03 Prevention and treatment of viral disease
BR9912732-6A BR9912732A (en) 1998-08-03 1999-08-03 Isolated molecular structure, enveloping and combining viruses, vaccine formulation, anti-corporomonoclonal, polyclonal antiserum, jelly, foam, contraceptive cream or ointment, mammal and human blood samples, kit, cell line, treatment processes or prevention of infection by a virus in subject, treatment or prevention of infection by a human infection, inhibition of infection by a virus in a blood sample, inhibition of infection by HIV in a human blood sample, decontamination of surgical or dental tools, monitoring of antibody product to molecular structure, production of an immunogen for use in a vaccine for treatment or prevention of infection by a virus, and production of an immunogen for use in a vaccine for the treatment or prevention of HIV infection, cross-linked structure, monoclonal antibody to the structure , decontamination of surgical or dental tools, pro selection process of a molecular structure for vaccine efficacy, mammal, isolated protein complex, devacin formulation, processes of immunization of an animal to a virus, and preparation of a protein complex, fixed cells, processes of purification of a protein complex and treatment of a host that has been exposed to a virus, or of preventing infection of a host by said virus, and composition.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9510598P 1998-08-03 1998-08-03
US60/095,105 1998-08-03
US14180699P 1999-06-29 1999-06-29
US60/141,806 1999-06-29

Publications (3)

Publication Number Publication Date
WO2000008043A2 WO2000008043A2 (en) 2000-02-17
WO2000008043A3 true WO2000008043A3 (en) 2000-05-11
WO2000008043A9 WO2000008043A9 (en) 2001-12-13

Family

ID=26789760

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/017487 Ceased WO2000008043A2 (en) 1998-08-03 1999-08-03 Prevention and treatment of viral disease

Country Status (9)

Country Link
EP (1) EP1102788A4 (en)
JP (1) JP2002522448A (en)
KR (1) KR20010085326A (en)
CN (1) CN1321165A (en)
AU (1) AU5771599A (en)
BR (1) BR9912732A (en)
CA (1) CA2338983A1 (en)
IL (1) IL141211A0 (en)
WO (1) WO2000008043A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
EP1141314A2 (en) 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
FR2789590B1 (en) * 1999-02-15 2003-01-17 Inst Rech Developpement Ird IMMUNOGENIC COMPOSITIONS FOR USE AS VACCINES
EP1130089A1 (en) * 2000-02-17 2001-09-05 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Composition comprising membrane virus subviral target and fusion particles and vaccine comprising said composition
EP1331942A4 (en) 2000-09-22 2005-03-16 Univ Duke IMMUNOGEN CONTAINING HIV-ENVELOPE PROTEIN RELATED TO A LIGAND
US7033593B2 (en) 2000-09-22 2006-04-25 Duke University Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
CA2431881C (en) * 2001-01-05 2011-02-22 Aventis Pasteur Polypeptide inducing hiv-neutralising antibodies
FR2819256B1 (en) * 2001-01-05 2004-04-30 Aventis Pasteur POLYPEPTIDE INDUCING HIV NEUTRALIZING ANTIBODIES
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
WO2005105841A2 (en) 2004-03-12 2005-11-10 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
GB201412494D0 (en) 2014-07-14 2014-08-27 Ospedale San Raffaele And Fond Telethon Vector production
WO2021096829A1 (en) 2019-11-11 2021-05-20 Vanderbilt University Human monoclonal antibodies to hantavirus and methods of use therefor
US20230273209A1 (en) * 2020-10-09 2023-08-31 Helmholtz Zentrum München - Deutsches Forschungszentrum Für Gesundheit Und Umwelt Method for determining whether or not virus-neutralizing antibodies are present and in vitro method for screening compounds for their ability to neutralize a virus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993005147A1 (en) * 1991-08-30 1993-03-18 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Defective interfering hiv particles with chimeric cd4-env
US5714316A (en) * 1991-06-21 1998-02-03 The Wistar Institute Of Anatomy & Biology Chimeric envelope proteins for viral targeting

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714316A (en) * 1991-06-21 1998-02-03 The Wistar Institute Of Anatomy & Biology Chimeric envelope proteins for viral targeting
WO1993005147A1 (en) * 1991-08-30 1993-03-18 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Defective interfering hiv particles with chimeric cd4-env

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10

Also Published As

Publication number Publication date
EP1102788A2 (en) 2001-05-30
KR20010085326A (en) 2001-09-07
AU5771599A (en) 2000-02-28
EP1102788A4 (en) 2002-08-28
IL141211A0 (en) 2002-02-10
WO2000008043A9 (en) 2001-12-13
WO2000008043A2 (en) 2000-02-17
CN1321165A (en) 2001-11-07
BR9912732A (en) 2001-11-27
JP2002522448A (en) 2002-07-23
CA2338983A1 (en) 2000-02-17

Similar Documents

Publication Publication Date Title
Osterhaus et al. Vaccination with Rev and Tat against AIDS
Fekadu et al. Efficacy of rabies vaccines against Duvenhage virus isolated from European house bats (Eptesicus serotinus), classic rabies and rabies-related viruses
Excler et al. Prospects for a globally effective HIV-1 vaccine
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
EP0330359A3 (en) Composition useful in the diagnosis and treating of hiv-1 infection
WO2005028625A3 (en) Consensus/ancestral immunogens
Wang et al. A trivalent HCV vaccine elicits broad and synergistic polyclonal antibody response in mice and rhesus monkey
WO2001000232A3 (en) Use of cpg as an adjuvant for hiv vaccine
CA2272338A1 (en) Immunization of infants
WO2022197720A3 (en) Compositions and methods for treating coronavirus infection
ATE508139T1 (en) SYNTHETIC PEPTIDE HIV VACCINE: THE CBD EPITOPE AS AN EFFICIENT IMMUNOGEN FOR THE INDUCTION OF HIV-NEUTRALIZING ANTIBODIES
BR9912732A (en) Isolated molecular structure, enveloping and combining viruses, vaccine formulation, anti-corporomonoclonal, polyclonal antiserum, jelly, foam, contraceptive cream or ointment, mammal and human blood samples, kit, cell line, treatment processes or prevention of infection by a virus in subject, treatment or prevention of infection by a human infection, inhibition of infection by a virus in a blood sample, inhibition of infection by HIV in a human blood sample, decontamination of surgical or dental tools, monitoring of antibody product to molecular structure, production of an immunogen for use in a vaccine for treatment or prevention of infection by a virus, and production of an immunogen for use in a vaccine for the treatment or prevention of HIV infection, cross-linked structure, monoclonal antibody to the structure , decontamination of surgical or dental tools, pro selection process of a molecular structure for vaccine efficacy, mammal, isolated protein complex, devacin formulation, processes of immunization of an animal to a virus, and preparation of a protein complex, fixed cells, processes of purification of a protein complex and treatment of a host that has been exposed to a virus, or of preventing infection of a host by said virus, and composition.
EP0142345A3 (en) Anti-idiotypic vaccine employing anti-idiotypic monoclonal antibodies
Konishi et al. Simultaneous immunization with DNA and protein vaccines against Japanese encephalitis or dengue synergistically increases their own abilities to induce neutralizing antibody in mice
Pedersen Jr et al. Separation, isolation, and immunological studies of the structural proteins of Venezuelan equine encephalomyelitis virus
Oduntan et al. The immunological response of Nigerian infants to attenuated and inactivated poliovaccines
US11780888B2 (en) Chimeric protein for coronavirus vaccine
WO2002022687A3 (en) Viral chemokine-tumur antigen fusion proteins
Brydak et al. Antibody response to influenza vaccination in healthy adults
Finerty et al. Mucosal immunization with experimental feline immunodeficiency virus (FIV) vaccines induces both antibody and T cell responses but does not protect against rectal FIV challenge
Vodopija et al. Rabipur: a reliable vaccine for rabies protection
Liao et al. Co‐delivery of a trimeric spike DNA and protein vaccine with aluminum hydroxide enhanced Th1‐dominant humoral and cellular immunity against SARS‐CoV‐2
NO175846C (en) Method of obtaining an immunogen
Decroix et al. Mucosal Immunity Induced by Intramuscular Administration of Free Peptides In‐Line with PADRE: IgA Antibodies to the ELDKWA Epitope of HIV gp41
Tafuku et al. Japanese encephalitis virus structural and nonstructural proteins expressed in Escherichia coli induce protective immunity in mice

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99811641.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2338983

Country of ref document: CA

Ref document number: 2338983

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 141211

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/001264

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020017001483

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 57715/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999945011

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999945011

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020017001483

Country of ref document: KR

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1-92, DESCRIPTION, REPLACED BY NEW PAGES 1-92; PAGES 93-104, CLAIMS, REPLACED BY NEW PAGES 93-104; PAGES 1/12-12/12, DRAWINGS, REPLACED BY NEW PAGES 1/23-23/23; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWW Wipo information: withdrawn in national office

Ref document number: 1999945011

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020017001483

Country of ref document: KR